Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.62 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924023 | 0.89 | NTRK1 (0.57) | NTRK1NTRK2KCNH2NTRK3 | |
| SCHEMBL14537222 | 0.88 | NTRK1 (0.67) | NTRK1NTRK2KCNH2NTRK3RET | |
| SCHEMBL1925611 | 0.84 | NTRK1 (0.71) | NTRK1NTRK2FLT3RETKDR | |
| SCHEMBL3980576 | 0.84 | NTRK1 (0.69) | NTRK1NTRK2FLT3RETKDR | |
| SCHEMBL1924948 | 0.84 | NTRK1 (0.69) | NTRK1NTRK2KCNH2NTRK3RET | |
| SCHEMBL1924266 | 0.83 | NTRK1 (0.67) | NTRK1NTRK2FLT3KCNH2NTRK3 | |
| SCHEMBL1925029 | 0.82 | NTRK1 (0.66) | NTRK1NTRK2KCNH2 | |
| SCHEMBL1924896 | 0.82 | NTRK2 (0.69) | NTRK1NTRK2KCNH2NTRK3RET | |
| SCHEMBL1924225 | 0.82 | NTRK1 (0.67) | NTRK1NTRK2KCNH2NTRK3 | |
| SCHEMBL1925123 | 0.81 | NTRK2 (0.81) | NTRK1NTRK2KCNH2NTRK3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | claimed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | claimed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | claimed |
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885FLT3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.